AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ)
$1.49 0.02 (1.3605%)
Analysed AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
10-04-2026
yahoo.com
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
08-04-2026
marketbeat.com
Autolus Therapeutics to Participate in Upcoming Investor Conferences
07-04-2026
yahoo.com
Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12
04-04-2026
yahoo.com
3 Promising Penny Stocks With Market Caps Over $100M
03-04-2026
yahoo.com
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
01-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
27-03-2026
yahoo.com
Autolus Therapeutics Q4 Earnings Call Highlights
27-03-2026
marketbeat.com
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
27-03-2026
yahoo.com
European Equities Traded in US as ADRs Fall in Wednesday Trading
18-03-2026
yahoo.com
What is the current price of AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ)?
The current price of AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) is $1.49.
AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) absolute price change since previous trading day?
The absolute price change of AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) since the previous trading day is $0.02.
AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) percentage price change since previous trading day?
The percentage price change of AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) since the previous trading day is 1.3605%.
What is the most recent average sentiment score for AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ)?
The most recent average sentiment score for AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ)?
The most recent sentiment for AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ) is .
SEC-8K** Filing Available For AUTOLUS THERAPEUTICS PLC (AUTL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.